A randomized controlled phase <scp>II</scp> clinical trial comparing <scp>ONO</scp>‐4053, a novel <scp>DP</scp>1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis

Abstract

We demonstrated that the efficacy of ONO-4053 was greater than that of pranlukast with a similar safety profile. This study indicates the potential of ONO-4053 for use as a treatment for SAR (JapicCTI-142706).